Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Researchers from Denmark published 12-month follow-up data from their ongoing, single-arm, phase 2 COMBI trial of low-dose pegylated interferon alfa-2 plus ruxolitinib in patients with low- to intermediate-risk myelofibrosis (MF) or polycythemia vera (PV), showing complete or partial remission and sustained complete hematologic responses (CHR) in 17% and 22% of patients with MF, respectively, and partial remission and CHR in 9% and 47% of PV patients, respectively.

 Cancer Medicine

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.